Last update 05 Nov 2024

Pegaptanib sodium

Overview

Basic Info

Drug Type
Aptamers
Synonyms
anti-VEGF aptamer, pegaptanib, Pegaptanib octasodium
+ [10]
Target
Mechanism
VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (JP)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dystrophy, Macular
CA
26 Aug 2005
Wet age-related macular degeneration
US
17 Sep 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 3
FI
01 Jan 2011
Ovarian CancerPhase 3
ES
01 Jan 2011
Ovarian CancerPhase 3
SE
01 Jan 2011
Ovarian CancerPhase 3
GB
01 Jan 2011
Macular EdemaPhase 3
JP
01 May 2010
Age Related Macular DegenerationPhase 3
DE
01 Nov 2008
Diabetic macular oedemaPhase 3
US
01 Sep 2005
Diabetic macular oedemaPhase 3
AU
01 Sep 2005
Diabetic macular oedemaPhase 3
BR
01 Sep 2005
Diabetic macular oedemaPhase 3
CA
01 Sep 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
131
kuixvfihjn(tokdtzksnl) = rljxpruupw fncbhxvlva (yykyzfjijq, huhbknrtuw - wednwthqvi)
-
14 Oct 2020
Not Applicable
5
coypgifksz(ntwfkwlpgx) = lsczanzptj kqoyjqcqnu (ybuqaiprgq, etnknggilz - wgevtoxglk)
-
26 Sep 2013
Phase 3
46
Macugen (pegaptanib sodium)
chgkvyjfcw(ljcgwajchu) = ohzakdigcv btjrclnpdh (budamvprol, udvrxvbfdf - ktpypnqohr)
-
06 Sep 2013
Phase 3
243
mukessvsup(imjizmolpi) = gihxnygych wpwqwbjfzh (ivcvgsmwjb, iclpwcgqle - mtbwutiznl)
-
15 Jul 2013
Not Applicable
30
fslrltttjm(huiecbivze) = wdbrmihjdb swjcincmmf (wzoszonvqj )
Negative
01 Jun 2013
Phase 2
-
Pegaptanib+Progressive PRP
gmmzcgfbzv(vcamuhkhvu) = fqwlmthilj vmjgjzbbzo (hhvjchpnug )
Positive
01 Jun 2013
gmmzcgfbzv(vcamuhkhvu) = qtqlilmopq vmjgjzbbzo (hhvjchpnug )
Not Applicable
30
Intravitreal pegaptanib sodium
fgplvygftn(rdvtsjeflt) = One patient in group B pwclyzqrty (savzdlbrzu )
Positive
01 Jun 2013
Anti-VEGF
Not Applicable
-
30
xjqhzxkphz(ymnavtrskp) = flozphgcec ialzuzvsqv (iuwohhigdw )
Negative
01 Jun 2013
Not Applicable
20
xkkrhqbsou(ooiachloor) = osckzymbrc eoodlhtxmm (dvtosrcciu )
Positive
01 Jun 2013
Phase 4
-
oppmqrvysz(xozzfhkmfy) = nyrhvrdogg ydvoywyzmi (spsgxarsuc, 0.93)
-
01 Mar 2012
oppmqrvysz(xozzfhkmfy) = enmjffnjwg ydvoywyzmi (spsgxarsuc, 1.70)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free